Felder C C, Glass M
Neuroscience Discovery, Eli Lilly Research Laboratory, Indianapolis, Indiana 46285, USA.
Annu Rev Pharmacol Toxicol. 1998;38:179-200. doi: 10.1146/annurev.pharmtox.38.1.179.
Marijuana has been in use for over 4000 years as a therapeutic and as a recreational drug. Within the past decade, two cannabinoid receptor types have been identified, their signal transduction characterized, and an endogenous lipid agonist isolated from mammalian tissues. The CB1 cannabinoid receptor is widely distributed in mammalian tissues, with the highest concentrations found in brain neurons. CB1 receptors are coupled to modulation of adenylate cyclase and ion channels. The CB2 receptor is found in cells of the immune system and is coupled to inhibition of adenylate cyclase. Both receptor types selectively bind delta 9-THC, the active principle in marijuana, and anandamide (arachidonylethanolamide), an endogenous cannabimimetic eicosanoid. Progress is being made in the development of novel agonists and antagonists with receptor subtype selectivity, mice with genetic deletion of the cannabinoid receptors, and receptor-specific antibodies, which should help in providing a better understanding of the physiological role of the cannabinoid receptors.
大麻作为一种治疗药物和娱乐性毒品已被使用了4000多年。在过去十年中,已鉴定出两种大麻素受体类型,表征了它们的信号转导,并从哺乳动物组织中分离出一种内源性脂质激动剂。CB1大麻素受体广泛分布于哺乳动物组织中,在脑神经元中浓度最高。CB1受体与腺苷酸环化酶和离子通道的调节有关。CB2受体存在于免疫系统细胞中,与腺苷酸环化酶的抑制有关。两种受体类型都选择性地结合大麻中的活性成分Δ9-四氢大麻酚和花生四烯酸乙醇胺(一种内源性大麻素样类二十烷酸)。在开发具有受体亚型选择性的新型激动剂和拮抗剂、大麻素受体基因缺失的小鼠以及受体特异性抗体方面正在取得进展,这将有助于更好地理解大麻素受体的生理作用。